Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of cct020312 as medicine for treating breast cancer or prostate cancer

A technology for prostate cancer and breast cancer, applied in the field of biomedicine, can solve the problems of lack of better targeted therapy drugs, large toxic and side effects, drug resistance of patients, and poor prognosis.

Pending Publication Date: 2020-07-17
CHONGQING MEDICAL UNIVERSITY
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to AR amino acid mutations or AR splicing variants, the affinity of drugs such as bicalutamide with AR is reduced, resulting in the inability of the drug to recognize AR, and patients have drug resistance and poor prognosis.
The second-generation AR antagonist enzalutamide has a better therapeutic effect, but it has central nervous system toxicity
In addition, triple negative breast cancer (TNBC) in breast cancer does not express estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). better targeted therapy
For TNBC, traditional first-line chemotherapy drugs, such as paclitaxel, are not effective in treating TNBC and have severe side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of cct020312 as medicine for treating breast cancer or prostate cancer
  • Application of cct020312 as medicine for treating breast cancer or prostate cancer
  • Application of cct020312 as medicine for treating breast cancer or prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1: CCT020312 inhibits PCa and TNBC cell viability and proliferation

[0066] CCK-8 experiment: Inoculate the cells in a 96-well plate, 180 μl per well, and set up a blank control group and a negative control group. After the cells adhere to the wall overnight, add different concentrations of CCT020312 to treat the cells for 24h or 48h, and discard the supernatant. After adding CCK-8 solution (CCK-8 stock solution: medium = 1:100) and incubating for 1-2 hours, use a microplate reader to detect the OD value of each well at 570 nm. Experimental results such as Figure 1-Figure 4Shown: CCK-8 test results show that after TNBC cells (MDA-MB-453, CAL-148) and PCa cells (LNCaP, C4-2) were treated with CCT020312 for 24h and 48h, the cell viability gradually decreased in a dose-dependent manner. After statistics and calculation: after CCT020312 treated MDA-MB-453 cells for 24 hours, the IC50 of CCT020312 was 7.047 μM; after CCT020312 treated MDA-MB-453 cells for 48 hours...

Embodiment 2

[0069] Example 2: CCT020312 induces PCa and TNBC cell apoptosis, autophagy and G1 phase arrest

[0070] Cell cycle detection by flow cytometry: cells were seeded in 6-well plates, and after adherence, different concentrations of CCT020312 were added to treat for 24 hours. After the cells were digested with trypsin, centrifuged at 1000r / min for 5min, the supernatant was discarded, washed twice with PBS, and centrifuged. Flow cytometric detection was performed after fixing with pre-cooled 70% absolute ethanol overnight. Experimental results such as Figure 11-Figure 14 As shown, CCT020312 can cause the G1 phase arrest of MDA-MB-453 cells and LNCaP cells, thereby affecting the cell cycle and inhibiting the proliferation of cancer cells.

[0071] Cell apoptosis detected by flow cytometry: cells were inoculated in 6-well plates, and treated with different concentrations of CCT020312 for 24 hours after adhering to the wall, after trypsinized cells, centrifuged at 1000r / min for 5min...

Embodiment 3

[0073] Example 3: Effect of CCT020312 on signaling pathways of PCa and TNBC cells

[0074] After using different concentrations of CCT020312 to treat MDA-MB-453 cells and C4-2 cells for 24h (for MDA-MB-453 cells, the drug concentration used was 0 μM, 6 μM, 8 μM and 10 μM; for C4-2 cells, the drug used Concentrations are 0 μM, 8 μM, 10 μM and 12 μM), and then use Western blot to detect the influence of CCT020312 on the signaling pathways of PCa and TNBC cells. The detection process is the same as the Western blot detection in Example 2, except that the detection objects are changed to PERK, p- PERK, ATF4, CHOP, p-eIF2α and eIF2α six PERK / eIF2α / ATF4 / CHOP pathway related proteins. Since prostate cancer and breast cancer are highly correlated with the expression level of androgen receptor (AR), this embodiment also detects the protein expression level of AR. For MDA-MB-453 cells, this experiment example also used 8μMCCT020312 to treat the cells (for MDA-MB-453 cells) for differen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biological medicine, relates to an application of CCT020312 as a medicine for treating cancer, and in particular relates to the application of CCT020312as the medicine for treating breast cancer or prostate cancer. The CCT020312 can be used for activating a PERK/eIF2alpha/ATF4 signal path and down-regulating AR expression to inhibit a PI3K/AKT/mTORsignal path, promote G1-phase retardation and cell autophagy of a cell cycle, and induce cell apoptosis to inhibit occurrence and development of the prostate cancer and the breast cancer. The CCT020312 can provide a novel strategy and thought for targeted therapy of refractory tumors dependent on male hormone receptors, and can be applied to medical practice of targeted therapy of the prostate cancer and the breast cancer.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and relates to the application of CCT020312 as a drug for treating cancer, in particular to the application of CCT020312 as a drug for treating breast cancer or prostate cancer. Background technique [0002] Prostate cancer (PCa) and breast cancer (BC) are sex hormone-dependent refractory tumors that endanger the health of men and women, with high heterogeneity. The current drugs for treating PCa are mainly androgen receptor (AR) antagonists, such as the first-generation bicalutamide and the second-generation enzalutamide. However, due to the mutation of AR amino acid or the generation of AR splicing variants, the affinity of drugs such as bicalutamide and AR is reduced, resulting in the inability of the drug to recognize AR, and the occurrence of drug resistance and poor prognosis in patients. The second-generation AR antagonist enzalutamide has a better therapeutic effect, but it has side ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/435A61P35/00
CPCA61K31/435A61P35/00
Inventor 周维英李小丽于晓萍周端方
Owner CHONGQING MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com